Anavex Life Sciences Corp (AVXL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anavex Life Sciences Corp (AVXL) has a cash flow conversion efficiency ratio of -0.120x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.54 Million) by net assets ($112.45 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AVXL market cap for the company's overall valuation and market capitalisation.
Anavex Life Sciences Corp - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Anavex Life Sciences Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Anavex Life Sciences Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anavex Life Sciences Corp ranked by their cash flow conversion efficiency. Explore AVXL cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taisun Enterprise Co Ltd
TW:1218
|
-0.005x |
|
Cantor Equity Partners I, Inc. Class A Ordinary Shares
NASDAQ:CEPO
|
N/A |
|
El-Mor Electric Installation & Services 1986 Ltd
TA:ELMR
|
0.136x |
|
Netronix
TWO:6143
|
-0.043x |
|
APRANGA AB EO 029
F:WHX
|
-0.031x |
|
ACP Holdings Acquisition Corp. Class A Ordinary Shares
NASDAQ:ACGC
|
N/A |
|
KABE Group AB (publ.)
ST:KABE-B
|
0.078x |
|
Sovereign Metals Ltd
AU:SVM
|
-0.527x |
Annual Cash Flow Conversion Efficiency for Anavex Life Sciences Corp (2004–2025)
The table below shows the annual cash flow conversion efficiency of Anavex Life Sciences Corp from 2004 to 2025. View Anavex Life Sciences Corp stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $94.87 Million | $-39.04 Million | -0.412x | -60.64% |
| 2024-09-30 | $120.26 Million | $-30.81 Million | -0.256x | -30.80% |
| 2023-09-30 | $141.85 Million | $-27.79 Million | -0.196x | -15.15% |
| 2022-09-30 | $142.49 Million | $-24.24 Million | -0.170x | +15.57% |
| 2021-09-30 | $150.82 Million | $-30.38 Million | -0.201x | +74.22% |
| 2020-09-30 | $27.24 Million | $-21.29 Million | -0.782x | +14.41% |
| 2019-09-30 | $20.29 Million | $-18.53 Million | -0.913x | -48.71% |
| 2018-09-30 | $20.49 Million | $-12.58 Million | -0.614x | -65.16% |
| 2017-09-30 | $24.25 Million | $-9.02 Million | -0.372x | +74.61% |
| 2016-09-30 | $6.31 Million | $-9.24 Million | -1.464x | -343.71% |
| 2015-09-30 | $12.81 Million | $-4.23 Million | -0.330x | +97.61% |
| 2014-09-30 | $192.63K | $-2.66 Million | -13.806x | -4473.47% |
| 2013-09-30 | $-2.46 Million | $-777.57K | 0.316x | -46.39% |
| 2012-09-30 | $-2.88 Million | $-1.69 Million | 0.589x | -82.31% |
| 2011-09-30 | $-1.14 Million | $-3.80 Million | 3.328x | +114.44% |
| 2010-09-30 | $-2.96 Million | $-4.59 Million | 1.552x | +114.21% |
| 2009-09-30 | $-3.86 Million | $-2.79 Million | 0.724x | -32.88% |
| 2008-09-30 | $-2.29 Million | $-2.47 Million | 1.079x | +53.48% |
| 2007-09-30 | $-462.50K | $-325.25K | 0.703x | -66.36% |
| 2006-09-30 | $-15.51K | $-32.43K | 2.091x | -10.93% |
| 2005-09-30 | $-26.02K | $-61.07K | 2.347x | +605.45% |
| 2004-09-30 | $25.61K | $-11.89K | -0.464x | -- |
About Anavex Life Sciences Corp
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), h… Read more